Skip to main content
Clinical Trials/CTRI/2016/06/007032
CTRI/2016/06/007032
Completed
Phase 2

Evaluation of Efficacy and Safety of AHPL/AYCAP/0413 capsule and AHPL/AYTOP/0213 cream in patients suffering from Acne Vulgaris - NI

Ari Healthcare Pvt Ltd0 sites63 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Acne Vulgaris
Sponsor
Ari Healthcare Pvt Ltd
Enrollment
63
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Ari Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Subjects suffering from acne vulgaris (mild, moderate and severe) as diagnosed by physician or dermatologist
  • 2\. Subject willing to participate in clinical trial and who have read, understood and signed informed consent form.
  • 3\. Subjects willing to make all required study visits
  • 4\. Subjects willing to follow study instructions given by the investigator

Exclusion Criteria

  • 1\.Patients with preexisting systemic disease necessitating long\-term medications.
  • 2\.Patients with history of genetic and endocrinal disorders.
  • 3\.Patients having menstrual disorders and patients with drug induced acne.
  • 4\.Patients having systemic/topical treatment for acne vulgaris since last 3 months.
  • 5\.Patients who are using any kind of face application for the management of acne.
  • 6\.Patients suffering from major/severe illness(s).
  • 7\.Patients having or given history of HIV, Hepatitis B or C, diabetes mellitus, hepatic/renal diseases and/or any other major skin disease(s).
  • 8\.Pregnant and lactating women
  • 9\.Subject having known hypersensitivity to any ingredient of investigational drugs .
  • 10\.Subjects with significant abnormal laboratory parameters

Outcomes

Primary Outcomes

Not specified

Similar Trials